Nozomi Oda is a partner of Morrison Foerster Law Offices. Her work focuses on cross-border public and private M&A, joint ventures, strategic investments, capital markets, and life sciences. Nozomi serves as co-head of Morrison Foerster’s Asia Private Equity practice.

She regularly advises clients on a wide range of Japanese regulations including securities, financial and fund, merger review, and healthcare and life sciences. In addition to her work in private practice, Nozomi spent two years with Japan’s Financial Services Agency (FSA) as a deputy director of the corporate disclosure department, where she participated in the drafting of the FSA’s disclosure regulations regarding private placement offerings and director compensation.

Nozomi is recommended in the 2023 edition of The Legal 500 Asia Pacific for Japan: Corporate and M&A and has also been recognized in The Best Lawyers in Japan for Capital Markets, Corporate and M&A, Private Equity, Private Funds and Venture Capital Law.

Nozomi is a bengoshi admitted to practice in Japan and New York and a member of the Dai-Ichi Tokyo Bar Association.

Nozomi’s experience includes representing:

• Daiichi Sankyo in its $6.9 billion global drug development and commercialization agreement with AstraZeneca.
• C.R. Bard in its acquisition of Medicon, a Japan-based distributor of medical equipment.
• Nissan Motor in its $2.3 billion acquisition of a 34% stake in Mitsubishi Motors.
• Starbucks Coffee in its buyout of the remaining 60.5% share of Starbucks Coffee Japan.